What is Immatics NV (IMTX) stock price today?

Immatics NV (IMTX) currently trades at $10.99 per share. The stock has a market capitalization of $1.50B and a P/E ratio of —x.

Is IMTX stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Immatics NV has a Smart Value Score of 25/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 2/9 and Altman Z-Score is 1.84.

What is Immatics NV's revenue and earnings?

Immatics NV has trailing twelve-month (TTM) revenue of $48.27M with profit margins of 0.00%. Earnings per share (EPS) is $-1.89.

Is Immatics NV financially healthy?

Immatics NV's Piotroski F-Score is 2/9 (weak financial health). The Altman Z-Score of 1.84 places it in the grey zone.

IMTX

Immatics NV

NASDAQ: IMTX · HEALTHCARE · BIOTECHNOLOGY

$10.99

-1.87% today

Updated 2026-04-30

Market cap

$1.50B

P/E ratio

—

P/S ratio

31.12x

EPS (TTM)

$-1.89

Dividend yield

—

52W range

$4 – $12

Volume

0.5M

Market cap

$1.50B

P/E ratio

—

P/S ratio

31.12x

EPS (TTM)

$-1.89

Dividend yield

—

52W range

$4 – $12

Volume

0.5M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

2.7

Growth

6.3

Quality

2.5

Profitability

5.0

Valuation

C+

2/9

Piotroski F-Score

Weak

1.8

Altman Z-Score

Grey zone

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$18.75

+70.61%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy9 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

Insufficient data

Risks

- Piotroski 2/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-58.58M

- Revenue declining -64.90% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$172.83M	$54.00M	$155.84M	$48.27M	$48.27M
Net income	$37.51M	$-96.99M	$15.22M	$-188.69M	$-27.95M
EPS	—	—	—	—	$-1.89
Free cash flow	$93.92M	$-12.73M	$-174.51M	$-175.95M	$-58.58M
Profit margin	21.71%	-179.63%	9.77%	-390.95%	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
IMTX	$1.50B	25	2.7	2.5	5.0	6.3	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Immatics NV trades at $10.99. Our Smart Value Score of 25/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 1.84, it sits in the grey zone. TTM revenue stands at $48.27M.

Frequently asked questions

What is Immatics NV's stock price?

Immatics NV (IMTX) trades at $10.99.

Is Immatics NV overvalued?

Smart Value Score 25/100 (Grade F, Strong Sell).

What is the price target of Immatics NV (IMTX)?

The analyst target price is $18.75, representing +70.6% upside from the current price of $10.99.

What is Immatics NV's revenue?

TTM revenue is $48.27M.

Piotroski F-Score?

2/9 — weak financial health.

Altman Z-Score?

1.84 — grey zone.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio31.12x

ROE-37.10%

Beta1.34

50D MA$10.27

200D MA$9.02

Shares out0.13B

Float0.07B

Short ratio—

Avg volume0.5M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

IMTX vs LLY →IMTX vs JNJ →IMTX vs ABBV →Stock screener →